Open AccessSecond-line therapy for advanced hepatocellular carcinoma with regorafenib or cabozantinib: Multicenter French clinical experience in real-life after matching
Author(s) -
Xavier Adhoute,
Marie De Matharel,
Laurent Mineur,
Guillaume Pénaranda,
Dann Ouizeman,
C. Toullec,
Albert Tran,
Paul Castellani,
Armelle Rollet,
Valérie Oulès,
H. Perrier,
Si Nafa Si Ahmed,
Marc Bourlière,
Rodolphe Anty
Publication year - 2022
Publication title -
world journal of gastrointestinal oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.924
H-Index - 26
ISSN - 1948-5204
DOI - 10.4251/wjgo.v14.i8.1510
Subject(s) - regorafenib , medicine , sorafenib , cabozantinib , hepatocellular carcinoma , propensity score matching , progression free survival , oncology , gastroenterology , liver cancer , progressive disease , liver disease , surgery , cancer , disease , overall survival , colorectal cancer
Starting a second-line systemic treatment for hepatocellular carcinoma (HCC) is a common situation. The only therapeutic options in France are two broad-spectrum tyrosine kinase inhibitors (TKIs), regorafenib (REG) and cabozantinib (CBZ), but no comparative real-life studies are available.